Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?

To: Madharry who wrote (1542)	2/6/2002 1:58:32 AM
From: John Metcalf	Read Replies (1) \| Respond to of 10345

"I cans see why ML used revenue target to estimate markt cap. " But they didn't do that, Harry. Most profitable biotechs and pharmas are trading at 10 X sales. With that metric, Elan would be conservatively valued at 10 X product sales, or $14B, or $43 per share. On a prospective earnings basis, ELN is trading at less than 10X the lowered earnings forecast, viz., P/E <10. And they are trading at 2 X cash/equivs, or 1.5 times equity. If you know of another company in any industry that I can buy at these low metrics, please tell me their ticker.